284 related articles for article (PubMed ID: 35339647)
21. Alternative splicing: a new breakthrough for understanding tumorigenesis and potential clinical applications.
Park J; Park J; Chung YJ
Genes Genomics; 2023 Apr; 45(4):393-400. PubMed ID: 36656436
[TBL] [Abstract][Full Text] [Related]
22. SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes.
Song X; Wan X; Huang T; Zeng C; Sastry N; Wu B; James CD; Horbinski C; Nakano I; Zhang W; Hu B; Cheng SY
Cancer Res; 2019 Oct; 79(20):5288-5301. PubMed ID: 31462429
[TBL] [Abstract][Full Text] [Related]
23. Role of Alternatively Spliced Messenger RNA (mRNA) Isoforms of the Insulin-Like Growth Factor 1 (IGF1) in Selected Human Tumors.
Kasprzak A; Szaflarski W
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977489
[TBL] [Abstract][Full Text] [Related]
24. Unproductive alternative splicing and nonsense mRNAs: a widespread phenomenon among plant circadian clock genes.
Filichkin SA; Mockler TC
Biol Direct; 2012 Jul; 7():20. PubMed ID: 22747664
[TBL] [Abstract][Full Text] [Related]
25. Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5' splice-site disruption.
Wimmer K; Roca X; Beiglböck H; Callens T; Etzler J; Rao AR; Krainer AR; Fonatsch C; Messiaen L
Hum Mutat; 2007 Jun; 28(6):599-612. PubMed ID: 17311297
[TBL] [Abstract][Full Text] [Related]
26. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
27. Roles and mechanisms of alternative splicing in cancer - implications for care.
Bonnal SC; López-Oreja I; Valcárcel J
Nat Rev Clin Oncol; 2020 Aug; 17(8):457-474. PubMed ID: 32303702
[TBL] [Abstract][Full Text] [Related]
28. Alternative splicing in cancers: From aberrant regulation to new therapeutics.
Song X; Zeng Z; Wei H; Wang Z
Semin Cell Dev Biol; 2018 Mar; 75():13-22. PubMed ID: 28919308
[TBL] [Abstract][Full Text] [Related]
29. Re-splicing of mature mRNA in cancer cells promotes activation of distant weak alternative splice sites.
Kameyama T; Suzuki H; Mayeda A
Nucleic Acids Res; 2012 Sep; 40(16):7896-906. PubMed ID: 22675076
[TBL] [Abstract][Full Text] [Related]
30. Alternative spliced variants as biomarkers of colorectal cancer.
Yi Q; Tang L
Curr Drug Metab; 2011 Dec; 12(10):966-74. PubMed ID: 21787266
[TBL] [Abstract][Full Text] [Related]
31. [Pre-mRNA alternative splicing in cancer: functional impact, molecular mechanisms and therapeutic perspectives].
Revil T; Shkreta L; Chabot B
Bull Cancer; 2006 Sep; 93(9):909-19. PubMed ID: 16980234
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence.
Tang Y; Horikawa I; Ajiro M; Robles AI; Fujita K; Mondal AM; Stauffer JK; Zheng ZM; Harris CC
Oncogene; 2013 May; 32(22):2792-8. PubMed ID: 22777358
[TBL] [Abstract][Full Text] [Related]
33. Cryptic splice site activation during RNA processing of MLL/AF4 chimeric transcripts in infants with t(4;11) positive ALL.
Divoky V; Trka JM; Watzinger F; Lion T
Gene; 2000 Apr; 247(1-2):111-8. PubMed ID: 10773450
[TBL] [Abstract][Full Text] [Related]
34. The landscape of alternative splicing in buccal mucosa squamous cell carcinoma.
Shah TM; Patel AK; Bhatt VD; Tripathi AK; Shah S; Shankar V; Joshi CG
Oral Oncol; 2013 Jun; 49(6):604-10. PubMed ID: 23566772
[TBL] [Abstract][Full Text] [Related]
35. Clinical and Functional Significance of TP53 Exon 4-Intron 4 Splice Junction Variants.
Pinto EM; Maxwell KN; Halalsheh H; Phillips A; Powers J; MacFarland S; Walsh MF; Breen K; Formiga MN; Kriwacki R; Nichols KE; Mostafavi R; Wang J; Clay MR; Rodriguez-Galindo C; Ribeiro RC; Zambetti GP
Mol Cancer Res; 2022 Feb; 20(2):207-216. PubMed ID: 34675114
[TBL] [Abstract][Full Text] [Related]
36. In vitro splicing analysis showed that availability of a cryptic splice site is not a determinant for alternative splicing patterns caused by +1G-->A mutations in introns of the dystrophin gene.
Habara Y; Takeshima Y; Awano H; Okizuka Y; Zhang Z; Saiki K; Yagi M; Matsuo M
J Med Genet; 2009 Aug; 46(8):542-7. PubMed ID: 19001018
[TBL] [Abstract][Full Text] [Related]
37. Single molecule analysis of c-myb alternative splicing reveals novel classifiers for precursor B-ALL.
Zhou YE; O'Rourke JP; Edwards JS; Ness SA
PLoS One; 2011; 6(8):e22880. PubMed ID: 21853052
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of splice-switching oligonucleotides.
Bauman J; Jearawiriyapaisarn N; Kole R
Oligonucleotides; 2009 Mar; 19(1):1-13. PubMed ID: 19125639
[TBL] [Abstract][Full Text] [Related]
39. Alternative splicing and cancer: a systematic review.
Zhang Y; Qian J; Gu C; Yang Y
Signal Transduct Target Ther; 2021 Feb; 6(1):78. PubMed ID: 33623018
[TBL] [Abstract][Full Text] [Related]
40. Genomic analysis of RNA alternative splicing in cancers.
Xing Y
Front Biosci; 2007 May; 12():4034-41. PubMed ID: 17485356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
